Ordina verkocht voor €5,75, ex-dividend

Ordina wordt van de beurs gehaald door de Franse sectorgenoot Sopra Steria. Het Franse bedrijf betaalt €5,75 per aandeel, nadat er nog dividend is uitgekeerd van €0,395 per aandeel.

Per saldo betekent dat dat aandeelhouders Ordina afscheid nemen op €6,14 per aandeel.

Grootaandeelhouders Teslin en Mont Cervin, samen goed voor 26% van de stukken, zijn akkoord.

De te betalen prijs is een premie van 36% op de slotprijs van 14 maart en 43% op de gemiddelde prijs van de laatste drie maanden.

Hier lees je het persbericht van Ordina.

De details:

• Conditional agreement reached on recommended all-cash public offer for all shares in Ordina at an Offer Price of EUR 5.75 ex-the proposed dividend[1] per share
• The Offer Price represents a premium of 36% over the closing price on 14 March 2023 and a premium of 43% to the last three months daily volume-weighted average price per share
• The combination creates a partner of choice in the BeNeLux IT consulting industry, accelerating the transformation towards a digital business partner
• The Offeror will support the continued growth of the combination in BeNeLux
• This acquisition would contribute to Sopra Steria’s balanced European expansion by developing its presence in geographical areas considered as strategic for Sopra Steria
• Ordina’s CEO Jo Maes will be responsible for the combined BeNeLux region
• Post-settlement, establishment of an integration committee in BeLux led by Ordina’s CEO and supported by Michel Lorgeré, the current CEO for Sopra Steria BeNeLux, to assure successful integration
• Ordina’s two largest shareholders, Teslin Participaties Cooperatief U.A. (“Teslin”) and Mont Cervin S.à r.l. (“Mont Cervin”), together holding approx. 26% of the Shares, have irrevocably agreed to tender their shares to the Offer; in addition, the Company’s CEO and CFO have also irrevocably agreed to tender their shares
• The transaction and its complementarities would result in an earnings per share[2] accretion of +1.2% in the first year (2024) and +3.7% in the second year (2025) for Sopra Steria.